Author: admin

ULTHERA DS 7-4.5 Ultherapy Transducer Anchors ALLWILL’s New Global Supply Initiative as Demand for Non-Invasive Body Tightening Surges

International medical aesthetics supply and service provider ALLWILL has officially launched a strategic global initiative aimed at streamlining the B2B supply chain for microfocused ultrasound (MFU-V) technologies. The market expansion focuses heavily on stabilizing the availability of certified, high-demand clinical consumables, anchored by the ULTHERA DS 7-4.5 Ultherapy Transducer.

This strategic move arrives amid significant regulatory updates within the aesthetic sector, notably the recent FDA clearances expanding MFU-V tissue-tightening indications to body applications, including the abdomen and arms. As clinics globally adapt to these larger surface areas—which require exponentially higher consumable line consumption per patient—the demand for reliable, verified deep-tissue probes has reached an all-time high. ALLWILL’s new operational framework addresses this exact bottleneck by ensuring consistent procurement channels paired with rigorous technical oversight.

Engineering Precision at the SMAS Layer

The ULTHERA DS 7-4.5 Ultherapy Transducer, traditionally designated as the “purple probe” within clinical environments, remains a foundational asset for non-invasive facial and neck lifting. Operating at a frequency of 7 MHz, the device is engineered to bypass superficial epidermal layers to deliver microfocused ultrasound energy precisely at a depth of 4.5 mm.

According to clinical data, this 4.5 mm focal point targets the Superficial Muscular Aponeurotic System (SMAS), the same fibromuscular matrix manipulated during surgical facelifts. By elevating localized tissue temperatures to an optimal 60–70°C, the transducer induces immediate thermal contraction of the collagen framework while stimulating long-term neocollagenesis. Over a subsequent two-to-three-month period, the gradual synthesis of new collagen fibers yields a visible lift and improved structural contouring without surgical downtime.

Unlike standard High-Intensity Focused Ultrasound (HIFU) alternatives, the genuine DS 7-4.5 transducer integrates proprietary DeepSEE® real-time imaging technology. This allows practitioners to visualize anatomical structures up to 8 mm deep before and during energy delivery. Industry analysts note that this “see-before-you-treat” capability serves as a vital safety barrier, protecting underlying bone, major blood vessels, and critical nerve paths from thermal injury, a feature that remains central to the platform’s market longevity.

Addressing the Cost Barriers of Multi-Depth Body Protocols

With the medical aesthetics market pivoting toward full-body skin tightening, practitioners are increasingly implementing multi-depth treatment protocols that combine 4.5mm deep lifting with 3.0mm dermal remodeling and 1.5mm superficial texturing. However, the high volume of lines required for body areas frequently compresses clinic profit margins due to rising consumable overheads.

ALLWILL’s newly unveiled global market strategy directly tackles this logistical challenge. By scaling the distribution of the DS 7-4.5 transducer alongside comprehensive equipment support, the company provides medical spas and dermatological practices with the supply-chain predictability needed to offer expanded treatment protocols profitably.

“The aesthetic industry is experiencing a distinct shift toward advanced visualization and multi-depth body applications,” stated a spokesperson for ALLWILL’s Global Procurement Division. “As consumable usage spikes, ensuring access to certified, reliable transducers becomes paramount. Our global strategy is designed to alleviate these procurement anxieties, ensuring medical professionals can maintain peak clinical performance while significantly optimizing their operational costs.”

Mitigating Risks via Advanced Biomedical Standardization

What distinguishes ALLWILL’s distribution model in the highly competitive B2B landscape is its heavy emphasis on technical validation. To eliminate the quality risks frequently associated with independent medical equipment sourcing, the company routes all inventory through its advanced Smart Center.

Operating as a centralized, data-driven processing facility, the Smart Center subjects every ULTHERA DS 7-4.5 Ultherapy Transducer and compatible aesthetic platform to exhaustive inspection, testing, and refurbishment protocols. Backed by one of the world’s largest third-party biomedical service networks, the facility cross-references every probe against strict performance parameters, checking for focal precision, acoustic power output, and pulse consistency.

This technical verification ensures that international practices receive equipment that performs strictly to original factory specifications. By coupling hardware distribution with extensive biomedical support, extended warranties, and practical clinical training, ALLWILL continues to elevate B2B standards, enabling practitioners to deliver safe, reproducible, and highly profitable patient outcomes worldwide.

For procurement details regarding the ULTHERA DS 7-4.5 Ultherapy Transducer or to review ALLWILL’s biomedical service portfolios, visit the company’s verified platform at https://allwillgroup.com.

About ALLWILL

ALLWILL is redefining B2B medical aesthetics by focusing on innovation, trust, and efficiency. Our mission is not just to sell devices but to solve the challenges practitioners face when sourcing, maintaining, and upgrading medical equipment. We achieve this through our industry-leading Smart Center, a comprehensive processing facility for device inspection, repair, and refurbishment, ensuring every machine meets rigorous performance standards.

With a commitment to transparency and data-driven solutions, ALLWILL empowers practitioners to make informed choices, optimizing performance while reducing costs. Our global reach, backed by the world’s largest third-party biomedical service facility, ensures that clients receive reliable, high-quality support at every step. From education and training to warranty and equipment services, ALLWILL delivers a seamless, trustworthy experience designed to elevate the standard of care in medical aesthetics.

Media Contact
Company Name: ALLWILL
Contact Person: Judy
Email: Send Email
Address:WORKSHOP UNIT 3 ON 1/F, RALEIGH CENTRE, NO.9 YIP CHEONG STREET, FANLING NEW TERRITORIES
Country: HongKong
Website: https://allwillgroup.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ULTHERA DS 7-4.5 Ultherapy Transducer Anchors ALLWILL’s New Global Supply Initiative as Demand for Non-Invasive Body Tightening Surges

Commercial Portable Dunk Tanks Now Available to Order Online, Direct from the Builder Mr Dunk Tank

“John and Linda of Mr Dunk Tank at the company’s Menifee, California headquarters. Mr Dunk Tank manufactures commercial-grade portable dunk tanks and replacement parts sold nationwide.”
Mr Dunk Tank has launched a new website that allows customers nationwide to order commercial dunk tanks and replacement parts directly online. Built by hand in California, the company’s portable and collapsible dunk tanks are now also available through Google Shopping, making it easier than ever for schools, churches, rental companies, and event organizers to purchase commercial-grad dunk tanks directly from the manufacturer.

MENIFEE, California – For years, every commercial dunk tank that left John’s workshop in Southern California was sold the same way: a phone call, an email, a handshake over the details. Now, for the first time, customers anywhere in the United States can order a Mr Dunk Tank directly online, as the company launches a fully redesigned website with complete e-commerce capabilities.

The new website at www.mrdunktank.com brings a streamlined buying experience to party rental companies, schools, churches, event organizers, and businesses seeking commercial-grade dunk tanks built for long-term, repeated use. Customers can now browse, compare, and securely purchase complete dunk tank systems as well as replacement parts, shipped directly from the manufacturer.

“I build every single dunk tank myself. Made with care, precision, and craftsmanship, and that will never change. And now our customers can go online, see what they are getting and order instantly and know it’s coming straight from the person who built it.” — John, Founder and Builder, Mr Dunk Tank

What began as a local California operation has grown into a nationally recognized supplier of commercial portable dunk tanks, driven almost entirely by word of mouth and the reputation of John’s handbuilt craftsmanship. The new website marks the company’s first major step into e-commerce, designed to meet growing demand without sacrificing the personal service the brand is known for.

Mr Dunk Tank products are also now available through Google Shopping, expanding discoverability for customers comparing commercial dunk tank options nationwide.

What Sets Mr Dunk Tank Apart

• Handbuilt by One Craftsman: Every tank is personally constructed by John in Menifee, CA. Customers are buying directly from the builder, not a factory.

• Replacement Parts Available: Unlike most competitors, Mr Dunk Tank sells replacement components, allowing rental operators and event organizations to extend the life of their equipment without replacing entire units.

• Portable and Collapsible Design: No trailer required. Units collapse flat for easy storage and transport while maintaining the commercial-grade durability needed for rental fleets and repeated event use.

• Heavy-Duty Commercial Construction: Powder-coated steel frames, heat-welded vinyl liners, and a clear viewing window built to withstand years of repeated use.

A Market Gap: Dunking Booth Replacement Parts

One of the most significant additions to the new website is a growing catalog of replacement parts, a category where Mr Dunk Tank stands virtually alone in the market. Most dunk tank manufacturers do not offer replacement components, leaving rental operators to either patch equipment with generic parts or replace entire units.

Mr Dunk Tank’s parts catalog changes that equation, allowing customers to extend the life of their investment with components shipped directly from the builder. For party rental companies especially, equipment downtime means lost revenue, and the right replacement part sourced directly from the manufacturer gets equipment back in service faster.

“When customers contact us, you will be talking directly to the people who built your dunk tank. That personal connection has always been important to us, and the new website is just one more way to make the experience even better.” — Linda, Customer Support, Mr Dunk Tank

The company’s signature portable and collapsible design remains a key differentiator in a market dominated by heavier trailer-mounted alternatives. Mr Dunk Tank units collapse to a 22 inch depth making storage and transport, an important practical advantage for rental companies managing multiple units and organizations with limited storage space.

Mr Dunk Tank Serves

• Party rental companies

• Schools and PTAs

• Churches and community organizations

• Fundraising events and festivals

• Event organizers and businesses

• Individual families and owners

To order online, visit www.mrdunktank.com/dunk-tanks-for-sale

About Mr Dunk Tank

Mr Dunk Tank is a California-based manufacturer of commercial dunk tanks and replacement parts. Every unit is built by hand in Menifee, California by founder John, who has personally constructed each tank the company has ever sold. Specializing in portable, collapsible, commercial-grade dunk tanks, Mr Dunk Tank serves rental companies, schools, churches, fundraisers, and events nationwide, with a focus on long-term durability, direct customer support, and equipment built to last.

Media Contact
Company Name: Mr Dunk Tank
Contact Person: Linda Kay Ganci
Email: Send Email
Phone: (949) 801-8000
Address:24010 Juanita Dr
City: Menifee
State: www.mrdunktank.com
Country: United States
Website: www.mrdunktank.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Commercial Portable Dunk Tanks Now Available to Order Online, Direct from the Builder Mr Dunk Tank

Mannix Marketing Wins Top Regional Awards for Marketing and Web Design

Mannix Marketing won two community-voted awards: Best Business Consulting/Marketing Services from The Post Star and Best Web Design Agency from Saratoga Today. COO Dani Pidgeon credited the wins to the team’s dedication to driving local business growth. Founded in 1996, the agency has spent over 30 years providing SEO, digital strategy, and web design across the Capital Region, while also operating major regional guides like Saratoga.com and LakeGeorge.com.

Mannix Marketing is celebrating a double win this month after bringing home top honors from two of the region’s biggest local business awards.

The agency was voted the winner for Best Business Consulting/Marketing Services in The Post Star’s Best of the Region awards, and was also named the Best Web Design Agency by Saratoga Today. As both of these awards are decided entirely by community votes, the wins highlight Mannix Marketing’s reputation for building great websites and helping local businesses grow.

“I am incredibly proud of our team’s relentless hard work and dedication,” said Dani Pidgeon, COO of Mannix Marketing. “These awards are a direct reflection of their commitment to delivering elite digital results and measurable growth for our local business community. Our clients’ success is our ultimate driver, and this regional recognition reinforces the tangible impact our team makes every single day.”

Mannix Marketing has spent over 30 years helping businesses across the Capital Region and the Adirondacks improve their online presence through local advertising options, SEO/GEO, digital strategy, and web design. These latest achievements reinforce the agency’s long-standing mission to ensure local, independent businesses can compete and thrive online.

To learn more about Mannix Marketing and its award-winning services, visit mannixmarketing.com.

About Mannix Marketing:

Founded in 1996 by Sara Mannix, Mannix Marketing is a digital marketing agency built on thirty years of ethical marketing practices and commitment to helping businesses achieve sustainable, measurable growth online. In addition to providing expert SEO, web design, and digital strategy, the company owns and operates a network of popular regional guides, including Saratoga.com, LakeGeorge.com, Albany.com, GlensFalls.com, and more. These platforms connect millions of residents and visitors with local businesses every year.

For more information on the company’s history and services, visit mannixmarketing.com

Media Contact
Company Name: Mannix Marketing
Contact Person: Dani Pidgeon
Email: Send Email
Country: United States
Website: https://www.mannixmarketing.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mannix Marketing Wins Top Regional Awards for Marketing and Web Design

Contempo Themes Launches AI-First Real Estate CRM with CRM-Wide AI Assistant

“The new CT Leads Pro AI Assistant provides context-aware guidance, lead intelligence, conversational CRM interaction, content generation, automation support, and live web search directly within the real estate workflow.”
New CT Leads Pro release brings conversational AI, live web search, automation, lead intelligence, and context-aware assistance directly into the real estate workflow.

Contempo Themes today announced a major advancement to CT Leads Pro, its real estate CRM platform, with the launch of a new CRM-wide AI Assistant designed to help real estate professionals manage leads, communicate with clients, automate repetitive tasks, and access information faster than ever before.

Unlike traditional real estate CRMs that treat AI as a standalone feature, CT Leads Pro introduces an AI-first experience where intelligent assistance is available throughout the platform. The new AI Assistant automatically understands the context of the page, lead, conversation, transaction, or activity an agent is viewing and provides relevant guidance, content generation, analysis, and research in real time.

“Most CRM platforms have added AI as a feature. We built AI into the core experience,” said Chris Robinson, Founder of Contempo Themes. “Real estate professionals shouldn’t have to jump between tools, search through records, or manually gather information. The AI Assistant helps agents work faster, stay organized, and focus more time on serving clients and closing transactions.”

Built on Nearly Two Decades of Real Estate Technology Experience

Since 2008, Contempo Themes has helped real estate professionals build and grow their businesses through websites, CRM technology, lead generation tools, and IDX-powered property search.

Today, the Real Estate 7 ecosystem serves:

  • 10,530+ customers
  • 20,470+ leads generated
  • 790+ five-star reviews
  • Thousands of agents, teams, and brokerages across residential, commercial, and land markets

The launch of the new AI Assistant represents the next evolution of CT Leads Pro and the company’s broader vision of delivering an intelligent platform that helps agents work more efficiently and provide a better client experience.

AI That Understands Your Business

The CRM-wide AI Assistant is available throughout CT Leads Pro and automatically understands the user’s current workflow and CRM context.

Agents can use natural language to:

  • Summarize lead activity and engagement
  • Review client communication history
  • Draft emails, text messages, and follow-up campaigns
  • Generate marketing content
  • Analyze lead behavior and trends
  • Surface important opportunities and risks
  • Research neighborhoods and communities
  • Search the web for real-time information
  • Access source-backed answers and citations
  • Receive intelligent recommendations and next-step suggestions

Example prompts include:

  • “Summarize this lead’s activity.”
  • “What properties has this client viewed most?”
  • “Draft a follow-up email.”
  • “Create a text message for this buyer.”
  • “Research this neighborhood.”
  • “What are current mortgage rate trends?”
  • “What should I do next with this lead?”

Because the AI Assistant is embedded directly into the CRM, agents can access answers and complete tasks without switching between multiple applications or browser tabs.

Why This Matters

Real estate professionals spend a significant portion of their day researching information, reviewing lead histories, drafting communications, updating records, and managing administrative tasks.

CT Leads Pro’s AI Assistant helps reduce that workload by allowing agents to interact with their CRM conversationally. Instead of navigating through multiple screens and reports, users can simply ask questions and receive immediate, context-aware answers.

The result is faster response times, improved lead management, greater productivity, and more time available for client-facing activities.

More Than a CRM

The AI Assistant is part of the broader CT Leads Pro CRM Growth Suite, which includes lead management, pipeline tracking, live chat, SMS messaging, scheduling, lead routing, automation rules, property recommendations, advanced reporting, AI-powered insights, and the new CRM-wide AI Assistant.

Together, these tools help agents manage their entire business from a single platform while leveraging AI to streamline day-to-day operations.

The new CRM-wide AI Assistant is available now as part of CT Leads Pro and the CRM Growth Suite.

Learn more at https://contempothemes.com/real-estate-crm/

About Contempo Themes

Founded in 2008, Contempo Themes develops software solutions for real estate professionals, including Real Estate 7, CT Leads Pro CRM, CT IDX Pro+, Automated Home Valuations, and AI-powered business tools. The company’s products help agents, teams, and brokerages generate leads, automate workflows, improve customer engagement, and grow their businesses through modern real estate technology.

Media Contact
Company Name: Contempo Creative Inc.
Contact Person: Chris Robinson
Email: Send Email
Address:1721 Paseo Ct
City: Ramona
State: https://contempothemes.com/real-estate-crm/
Country: United States
Website: https://contempothemes.com/real-estate-crm/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Contempo Themes Launches AI-First Real Estate CRM with CRM-Wide AI Assistant

Speciality Coffee Canada Broadens Its Roaster Roster with Rosso, Escape and Momus Paris

“Momus coffee is exclusive high end coffee roasted in Paris. In Northern America, Momus coffee is available only at Specialitycoffee.ca”
Montreal-based online retailer Speciality Coffee Canada has added three roasters to its curated catalogue — Calgary’s Rosso Coffee, Quebec’s Escape Coffee Roasters, and France’s Momus Paris — widening the range of origins, processes and roast styles available to customers across Canada and the United States.

Speciality Coffee, a Montreal-based online retailer specialising in speciality coffee beans sourced from leading roasters worldwide, has announced the addition of three new roasters to its catalogue: Rosso, Escape, and Momus Paris.

The additions extend a catalogue that already spans roasters across Canada, the United States, Europe, and Asia and Oceania. The company curates beans by origin, processing method and roast level, ranging from light filter lots to espresso blends, and ships across Canada and the United States.

The three new partners broaden that range further. Rosso, a roaster based in Calgary, Alberta, joins the catalogue’s Canadian selection with offerings that include single-origin lots from Honduras, Ethiopia and Indonesia. Escape, a Quebec roaster, brings a lineup that mixes approachable everyday coffees with seasonal and decaffeinated options. Momus Paris, based in France, adds a European perspective to the platform’s growing roster of international roasters.

For Canadian drinkers, the expansion is intended to deepen the choice on offer rather than simply enlarge it. By placing roasters from three different regions alongside one another, the retailer aims to make it easier for customers to compare processing styles and roast approaches in one place — part of its stated goal of giving buyers access to some of the best coffee beans Canada can source.

“Adding Rosso, Escape and Momus Paris reflects how we think about curation — bringing together distinct roasting philosophies from different parts of the world so customers can explore them side by side,” said Andrew, the founder of Speciality Coffee Canada. “Each of these roasters has its own approach to sourcing and roasting, and that variety is exactly what our customers are looking for.”

The roasters are available now through the company’s website, with the same shipping coverage across Canada and the United States that applies to its existing catalogue. The retailer notes that its selection continues to evolve as new lots and seasonal releases become available.

About Speciality Coffee Canada

Speciality Coffee Canada is a Montreal-based online retailer offering premium specialty coffee beans from leading roasters in Canada, the United States, Europe, and Asia and Oceania. The company curates its selection by origin, process and roast precision, with freshly roasted beans shipped across Canada and the United States. More information is available at specialitycoffee.ca.

Media Contact
Company Name: Speciality coffee
Contact Person: Andrew
Email: Send Email
City: Montreal
State: https://specialitycoffee.ca/
Country: Canada
Website: https://specialitycoffee.ca/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Speciality Coffee Canada Broadens Its Roaster Roster with Rosso, Escape and Momus Paris

Essay Grader AI Ranks #1 in Expert Review of Best AI Essay Graders for Teachers in 2026

“Independent analysis evaluates 6 AI essay grading platforms across speed, accuracy, standards alignment, academic integrity, student privacy, and LMS integration. Essay Grader AI emerges as the purpose-built classroom solution recognized by OpenAI alongside Duolingo and Canva as one of the fastest-growing EdTech companies in its ecosystem.”
Independent analysis evaluates 6 AI essay grading platforms across speed, accuracy, standards alignment, academic integrity, student privacy, and LMS integration. Essay Grader AI emerges as the purpose-built classroom solution recognized by OpenAI alongside Duolingo and Canva as one of the fastest-growing EdTech companies in its ecosystem.

TORONTO, ON – June 3, 2026 – Essay Grader AI (essaygrader.ai) is thrilled to announce its #1 ranking as “Best Overall AI Essay Grading Platform for Teachers” in an independent expert review of the 6 best AI essay graders for teachers in 2026, conducted by education technology reviewers evaluating platforms across grading speed, accuracy, standards alignment, academic integrity, student privacy, learning management system integration, batch processing capability, and overall scalability for classroom use.

The comprehensive expert review distinguished Essay Grader AI through a defining recognition that sets it apart from generic AI tools repurposed for education: the platform has been identified by OpenAI as one of the fastest-growing EdTech companies within its ecosystem, alongside industry giants like Duolingo and Canva. Trusted by over 100,000 teachers and 1,000+ schools and colleges worldwide including Clemson University, La Vernia ISD, Brockton Public Schools, Sacramento City Unified School District, and Conejo Valley Unified School District, Essay Grader AI has proven that purpose-built educational AI can deliver dramatic time savings without sacrificing feedback quality or student data privacy.

“When it comes to purpose-built AI grading tools, Essay Grader AI stands in a class of its own,” states the expert analysis. The review emphasizes that the platform “is not a generic AI tool repurposed for grading; it is a dedicated solution that understands the specific challenges teachers face at every grade level and subject area,” highlighting how the platform was built from the ground up with educators in mind.

Essay Grader AI delivers comprehensive capabilities that experts identified as essential for 2026 classroom deployment:

OpenAI-Recognized EdTech Growth Leader

  • Identified by OpenAI as one of the fastest-growing EdTech companies in its ecosystem
  • Recognized alongside industry leaders Duolingo and Canva for category-defining growth
  • Trusted by 100,000+ teachers managing real classroom workloads
  • 1,000+ schools and colleges actively grading with the platform
  • Over 1 million students receiving feedback through Essay Grader AI
  • 4.8/5 Trustpilot rating reflecting consistent educator satisfaction
  • Featured in CNN, Associated Press, Hechinger Report, and Educating America Today

80% Grading Time Reduction at Scale

  • Reduces grading time by 80% across hundreds of essays
  • Grade an entire class in minutes rather than evenings and weekends
  • Built-in batch processing handles 30 to 300 students with equal ease
  • Real-time grading progress updates while the platform handles the work
  • Less than 4% variance compared to human grading based on a study of 1,000+ essays
  • Used by one of the largest alternate teaching certification programs in the world, grading over 200,000 assignments
  • Reclaims evenings, weekends, and school breaks previously lost to paper grading

Consistency and Bias Elimination

  • Removes the natural standard drift that occurs when teachers grade dozens of papers across a single week
  • Every essay evaluated against the same standards every time
  • Calibrated scoring provides confidence that results are fair and accurate across the board
  • Eliminates inconsistency caused by fatigue, time of day, or reader mood
  • Side-by-side panel view showing student work and feedback together for teacher review
  • Teacher remains in the loop with full review and adjustment capability before sharing

Comprehensive Standards Alignment

  • Aligns with all 50 U.S. state academic standards out of the box
  • Native support for Texas STAAR, Florida B.E.S.T., CAASPP, and Arkansas ATLAS
  • College Board AP and Common Core State Standards built in with state-specific adaptations
  • International Baccalaureate framework support for IB programs worldwide
  • Cambridge, British, Australian, Canadian, New Zealand, and Singapore frameworks supported
  • No manual rubric configuration required for state-specific assessment requirements
  • Works across ELA, history, social studies, and any essay-based subject

500+ Rubrics Library and Full Custom Rubric Control

  • Library of 500+ prebuilt rubrics aligned to state, national, and international standards
  • Teachers retain full control over how every assignment is graded
  • Upload custom rubrics including CCSS, AP LEQ, and IB frameworks
  • Create a custom rubric in under one minute by uploading existing rubric files
  • Set custom criteria for each individual assignment
  • Coverage spans every grade level, genre, and assessment type
  • Build a rubric that matches exactly what your classroom needs

Built-In Academic Integrity Tools

  • AI writing detection identifying generative AI content with high accuracy
  • Built-in plagiarism detection flagging copied or overlapping work
  • Submissions flagged for teacher review rather than automatically penalized
  • Confidence that teachers are assessing genuine student work
  • Increasingly essential as generative AI tools become widely accessible to students in 2026
  • Teacher remains in control of every flagged submission outcome

Native LMS Integrations Without Middleware

  • Direct integration with Google Classroom with over 500,000 assignments graded to date
  • Native Canvas LMS integration with over 400,000 assignments graded to date
  • Schoology integration available for districts using that platform
  • No third-party middleware required for any integration
  • Import assignments, grade them, and sync grades back in just a few clicks
  • Eliminates app-hopping, downloading, renaming, and re-uploading individual files
  • Grades sync back to Canvas SpeedGrader for streamlined workflow

One-Click Bulk Upload From Cloud Storage

  • Upload entire class submissions in a single click from Google Drive
  • Direct upload from OneDrive for districts using Microsoft ecosystems
  • Eliminates the tedious process of downloading, renaming, and re-uploading files one by one
  • Real-time progress updates while submissions are graded in the background
  • Designed for the realities of high-volume essay assignments

Immediate, Detailed Feedback for Students

  • Students receive detailed feedback in minutes rather than days
  • Feedback covers content, style, grammar, and rubric-specific criteria
  • Specific, actionable comments rather than generic suggestions
  • Side-by-side view shows student work and feedback together
  • Feedback delivered while students still remember writing the essay, when it is most actionable
  • Teachers can edit and adjust feedback before sharing with students
  • Option to send feedback reports with or without the numerical score

Performance Insights at Every Level

  • Data-driven insights at the individual student, assignment, and class levels
  • Track student writing growth over time across the school year
  • Identify patterns in writing strengths and gaps across a class
  • Inform instructional decisions with concrete writing data
  • Export grades and reports from a unified dashboard
  • Calibrated, measurable growth data invaluable for guiding instruction at the school and district level

Multi-Language and Regional Support

  • Grading support for Spanish, French, Chinese, Japanese, and additional languages
  • Configure input language and feedback language independently
  • U.S., U.K., and Australian English support for regional accuracy
  • Spanish teachers in the U.S. can receive feedback in either Spanish or English
  • Supports paper grading across diverse student populations and dual-language programs

Enterprise-Grade Student Privacy and Security

  • Student names, emails, and IDs are never required to grade assignments
  • AES-256 encryption for all submissions and grading results at rest
  • TLS (HTTPS) encryption for all data in transit
  • Student work remains fully owned by the teacher and school
  • Submissions are never used to train AI models, resold, or shared with third parties
  • Teachers can delete submissions, grades, or entire accounts at any time
  • FERPA, COPPA, SOPPA, and PIPEDA compliant
  • NIST SP 800-53 compliance standards adhered to
  • SOC 2 Type I certified with comprehensive security documentation
  • Independently evaluated for data protection and responsible AI usage
  • Digital Privacy Agreements (DPAs) executed with schools and districts across 30+ U.S. states

Beyond Essay Grading

  • Grades short answers, DBQs, research reports, case studies, journals, and summaries
  • Supports argumentative, informative, narrative, and analytical essay types
  • Works for AP courses, state standardized test prep, and custom assignments
  • AI Essay Summarizer extracts key details for quick grading review
  • AI Rubric Generator, Thesis Checker, and AI Question Generator included
  • College Essay Grader, EZ Grader Calculator, LOR Generator, and Worksheet Generator extend classroom utility

Free Tier and Onboarding Support

  • Every teacher can grade 25 essays per month completely free
  • Two free certification courses available for educators wanting deeper platform mastery
  • Live onboarding training session included with every school purchase
  • Schools completing expert-led onboarding see a 30% increase in adoption and platform usage
  • Built for Teachers by Teachers, not big tech

The expert review emphasizes how Essay Grader AI directly addresses the highest-friction pain points in modern classroom grading. “One of the most significant pain points in essay grading is inconsistency,” states the analysis, explaining how grading 90 papers across a single week causes standards to shift subtly throughout the workload. According to the review, Essay Grader AI “eliminates that problem entirely by removing human bias from the scoring process and ensuring every essay is evaluated against the same standards.”

The review identifies the OpenAI recognition as significant validation of category leadership. The platform’s identification by OpenAI as one of the fastest-growing EdTech companies in its ecosystem, alongside industry giants like Duolingo and Canva, places Essay Grader AI in rarified company among consumer education products that have fundamentally transformed how millions of learners and educators engage with their daily work. The expert review notes this recognition reflects “the trust it has built among educators who have made it a cornerstone of their grading workflow.”

Real-world educator testimonials validate the expert conclusions. One AP English teacher reported being “stunned” by how closely the AI grading matched scores she had previously assigned manually, with feedback that was “concrete and specific.” A Grade 6 writing teacher described the platform as a tool that lets her give students the corrective feedback they need so they are “less likely to make those mistakes in the future.” Middle and high school English teachers report saving 5 to 6 hours per week of grading time while delivering more thorough feedback than was previously possible at scale.

Educational leaders emphasize the broader institutional value. One superintendent describes the platform as ensuring “essays are graded equally, and from a data perspective, the calibrated scores provide confidence that results are fair and accurate across the board.” A school principal highlights how the calibrated, measurable growth data has become invaluable for guiding instruction and supporting student progress at the building level. These institutional perspectives reflect why Essay Grader AI has been adopted across K-12 classrooms, AP programs, IB programs, university courses, and one of the largest alternate teaching certification programs in the world.

The expert review concludes with a clear recommendation for educators evaluating the category: “For teachers who want the most complete and capable solution available, Essay Grader AI delivers on every dimension that matters: speed, accuracy, standards alignment, academic integrity, student privacy, and seamless integration. Its recognition by OpenAI as one of the fastest-growing EdTech platforms is a reflection of the trust it has built among educators who have made it a cornerstone of their grading workflow.”

With AI essay grading shifting from experimental technology to standard classroom practice in 2026, Essay Grader AI represents the category-defining solution purpose-built for the realities of K-12 and higher education classrooms. The platform combines speed, depth, compliance, and integration in a single dedicated product engineered specifically for educators rather than retrofitted from general-purpose AI tools. As the expert review concludes: “Whatever tool you choose, the goal remains the same: spend less time managing paper and more time doing what matters most, teaching.”

About Essay Grader AI

Essay Grader AI (essaygrader.ai) is the expert-reviewed #1 AI essay grader for teachers in 2026, recognized by OpenAI as one of the fastest-growing EdTech companies in its ecosystem alongside industry leaders Duolingo and Canva. Trusted by 100,000+ teachers, 1,000+ schools and colleges, and over 1 million students worldwide, Essay Grader AI reduces grading time by 80% while delivering rubric-aligned feedback on content, style, and grammar. The platform aligns with all 50 U.S. state academic standards including Texas STAAR, Florida B.E.S.T., CAASPP, and Arkansas ATLAS, plus international frameworks including IB, Cambridge, British, Australian, Canadian, New Zealand, and Singapore standards. With native Google Classroom, Canvas, and Schoology integrations, 500+ prebuilt rubrics, custom rubric upload, AI writing detection, plagiarism detection, multi-language support, AES-256 encryption, and FERPA, COPPA, SOPPA, PIPEDA, and SOC 2 Type I compliance, Essay Grader AI is the privacy-first, standards-aligned grading platform built for teachers by teachers. Every educator can grade 25 essays per month free at essaygrader.ai.

Media Contact
Company Name: Essay Grader AI (essaygrader.ai)
Contact Person: Chan Yerneni
Email: Send Email
City: Toronto
Country: Canada
Website: https://www.essaygrader.ai/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Essay Grader AI Ranks #1 in Expert Review of Best AI Essay Graders for Teachers in 2026

As the Duduk Finds a Global Audience, Duduk.Rocks Spotlights Its Professional Armenian Instruments

“Duduk.Rocks: Professional Armenian Duduk Instruments”
Duduk.Rocks, a leading distributor of professional Armenian duduks, is highlighting its range of master-crafted instruments — including the MKS professional duduk, Sahak Gasparyan’s bass duduk, and the DuClar — as international interest in Armenia’s national instrument continues to grow.

Duduk.Rocks, a retailer specialising in handcrafted Armenian instruments, is drawing attention to its lineup of professional-grade duduks as the centuries-old duduk instrument continues to attract players and listeners well beyond Armenia.

Once heard primarily in Armenian folk traditions, the duduk has in recent decades become a fixture of film scores, jazz, world music and meditation recordings. That widening appeal has brought a new international audience to the instrument — and, with it, growing demand for instruments made to a professional standard.

Based in Lippstadt and shipping internationally, Duduk.Rocks describes itself as one of the largest distributors of professional Armenian duduks, working directly with established Armenian master craftsmen. The company’s catalogue spans instruments suited to beginners and advanced players alike, alongside reeds, cases, books and learning resources.

Among the instruments the company is highlighting is the MKS duduk, a professional model in A produced by the workshop of master maker Karen Mukayelyan. Built for serious players, it reflects the precision and tonal consistency that distinguish professional-tier instruments from entry-level alternatives.

The company is also featuring the work of master craftsman Sahak Gasparyan, whose bass duduk in A offers the deeper register increasingly sought by recording musicians and ensemble players. Gasparyan’s instruments appear across several of the company’s collections, in a range of tonewoods.

Rounding out the spotlight is the DuClar, a modern hybrid instrument in the duduk family that broadens the expressive options available to contemporary players exploring the duduk’s sound in new musical settings.

The company frames its work as preservation as much as commerce. Its stated mission includes supporting the Armenian artisans who keep the tradition alive and ensuring the instrument’s distinctive voice reaches future generations. Personal consultation is a central part of its approach: because every musician’s needs differ, the company advises players individually on selecting an instrument suited to their level, repertoire and budget.

“The duduk speaks to people in a way few instruments do, and that emotional connection is what continues to draw new players to it,” said Arthur, spokesman of Duduk.Rocks. “Our role is to make genuinely professional instruments — and the craftsmanship behind them — accessible to that growing community.”

The full range of professional duduks and related instruments is available through the company’s website, with international shipping from Germany.

About Duduk.Rocks

Duduk.Rocks GbR is a Germany-based retailer of professional Armenian duduks and related instruments, working directly with Armenian master craftsmen. Based in Lippstadt, the company offers handcrafted instruments, reeds, cases, sheet music and educational resources, and ships internationally. More information is available at duduk-rocks.com.

Media Contact
Company Name: Duduk Rocks
Contact Person: A. Demurchyan
Email: Send Email
Country: Canada
Website: https://duduk-rocks.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: As the Duduk Finds a Global Audience, Duduk.Rocks Spotlights Its Professional Armenian Instruments

How to Hire a Local Contractor Without Relying on Star Ratings or Blind Trust

“GigNGo — See Who You’re Hiring Before You Hire Them”
Star ratings can be faked. Reviews can be fabricated. GigNGo gives homeowners a better way to hire local contractors — through short-form video that lets them see exactly who they’re hiring, how they work, and whether they’re the right fit before a single message is sent.

GRAND RAPIDS, MI – June 23, 2026 – Hiring a local contractor has always required a leap of faith. You find a name on a platform, read a handful of reviews, look at a star rating, and decide whether to let a stranger into your home based on information you have no real way to verify.

Star ratings can be gamed. Reviews can be fabricated. Profile photos can be stock images. And the platforms that host all of it have a financial incentive to show you whoever paid the most for visibility — not necessarily whoever is the best fit for your job.

So how do you actually hire a local contractor you can trust in 2026?

The answer is shifting away from ratings and toward something more reliable: video.

GigNGo is a local services marketplace built around the belief that seeing is more trustworthy than reading. Instead of browsing static profiles sorted by star rating, homeowners on GigNGo open the GigFeed — a short-form video discovery feed where workers show their actual work, their communication style, and their professional personality before any money changes hands.

A homeowner looking for a painter can watch a worker explain his process, show his prep work, and walk through a finished room before deciding to reach out. Someone needing lawn care can see exactly how a landscaper treats a yard, how they communicate with clients, and what their finished work actually looks like. The decision to hire stops being a gamble and starts being an informed choice — made the same way people make every other trust decision online: by watching.

“Star ratings were the best tool available when these platforms were built,” said Cameron Lockrey, Founder of GigNGo. “But they were always a proxy for trust — not trust itself. Video is trust itself. When you watch someone work, you know immediately whether they are the right person for your job.”

Beyond the discovery experience, GigNGo’s model is structurally designed to attract better workers. Because the platform charges a flat monthly subscription rather than taking a commission on completed jobs, workers on GigNGo are not financially squeezed by the platform. They keep 100% of every dollar they earn — which means they show up motivated to do great work and build their reputation, not just close transactions.

Every worker profile on GigNGo is Google-indexed and permanently discoverable — meaning the content a worker posts compounds over time, building a verifiable professional track record that homeowners can reference before making a hiring decision.

GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces. For homeowners who have been burned by unreliable contractors found through star-rating platforms, or who have spent too long posting in Facebook Groups and hoping for the best — GigNGo is the hiring experience that was always missing.

Workers and homeowners can join GigNGo today at gigngo.org or by downloading the app on iOS and Android.

About GigNGo

GigNGo (gigngo.org) is a workers-first local services marketplace founded by Cameron Lockrey. The platform allows workers to keep 100% of their earnings through a flat monthly subscription, while employers post jobs for free. GigNGo’s GigFeed — a TikTok-style short-form video discovery feed — lets workers build personal brands so their character gets them the job. GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces.

Media Contact
Company Name: GigNGo
Contact Person: Cameron Lockrey
Email: Send Email
Phone: 5304339682
Address:2951 Englewood Ave
City: Grand Rapids
State: https://gigngo.org
Country: United States
Website: https://gigngo.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How to Hire a Local Contractor Without Relying on Star Ratings or Blind Trust

Aplastic Anemia Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui

The Key Aplastic Anemia Companies in the market include – Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others.

 

DelveInsight’s “Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Get a Free sample for the Aplastic Anemia Market Report

https://www.delveinsight.com/sample-request/aplastic-anemia-market

 

Some of the key facts of the Aplastic Anemia Market Report:

  • The Acromegaly market size was valued at approximately USD 1.3 billion in 2025 and is expected to experience steady growth during the forecast period from 2026 to 2036, registering a CAGR of around 1.5%.

  • Regeneron announced in 2025 that they have discontinued the study of REGN7257 in Aplastic anemia.

  • In February 2026, Ayrmid announced presentation of additional positive results for OMISIRGE in treating SAA at TANDEM 2026.

  • In April 2025, Cellenkos announced that the US FDA had granted ODD to its novel cell therapy product, CK0801. Cellenkos was planning for a registration trial of CK0801 in H2 2025.

  • In December 2025, Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent organization of Gamida Cell Inc., a pioneer in cell therapy innovation, has announced that the U.S. Food and Drug Administration (“FDA”) has approved Omisirge (Omidubicel-onlv) for treating Severe Aplastic Anemia (SAA).

  • In September 2025, Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy sourced from cord blood. Marketed as Omisirge®, it is approved for adults and pediatric patients aged 12 and older with hematologic malignancies who are scheduled for umbilical cord blood transplantation following myeloablative conditioning, aiming to shorten neutrophil recovery time and lower the risk of infection.

  • According to DelveInsight’s analysis, the Aplastic anemia market across the 7MM reached approximately USD 300 million in 2025, with the US holding the largest share.

  • The overall market of Aplastic anemia in the 7MM is expected to cross USD 300 million by 2036.

  • The aplastic anemia market is projected to decline from 2026 onward, driven by the anticipated entry of generic versions of PROMACTA.

  • Treatment for SAA in the elderly is uncertain, considering both illness characteristics and the patient’s health to minimize treatment-related risks. Hematopoietic cell transplantation (HCT) is often a second-line choice for elderly SAA patients.

  • As per DelveInsight estimates, the total incident population of aplastic anemia in the 7MM was around 2,600 cases in 2025. These cases are projected to increase during the forecast period.

  • Japan accounted for the highest Incident cases of aplastic anemia in the 7MM in 2025, with approximately 850 cases.

  • In the United States, it is observed that aplastic anemia occurs primarily in the age group of 60 years and above, accounting for ~56% of all cases, in 2025.

  • Among EU4 and the UK, Germany accounted for the highest number of aplastic anemia cases, followed by France, whereas Spain accounted for the lowest number of cases in 2025.

  • Among the severity-specific cases, SAA was more common in the United States, with ~430 cases in 2025.

  • Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

  • Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

  • The Aplastic Anemia epidemiology based on gender analyzed that the male-to-female ratio is approximately 1:1

  • The Aplastic Anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aplastic Anemia pipeline products will significantly revolutionize the Aplastic Anemia market dynamics.

 

Aplastic Anemia Overview

According to the National Institutes of Health, pancytopenia and decreased or nonexistent hematopoietic precursors in the bone marrow are symptoms of aplastic anaemia, which is a state of chronic primary hematopoietic failure brought on by damage.

 

To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast

 

Aplastic Anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Aplastic Anemia Epidemiology Segmentation:

The Aplastic Anemia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of Aplastic Anemia

  • Severity-specific Cases of Aplastic Anemia

  • Age-specific Cases of Aplastic Anemia

 

Download the report to understand which factors are driving Aplastic Anemia epidemiology trends @ Aplastic Anemia Epidemiology Forecast

 

Aplastic Anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Aplastic Anemia market or expected to get launched during the study period. The analysis covers Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Aplastic Anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Aplastic Anemia Therapies and Key Companies

  • OMISIRGE (omidubicel-onlv): Ayrmid (Gamida Cell)

  • ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

  • ROMIPLATE (romiplostim): Kyowa Kirin

  • CK0801: Cellenkos

  • ALVAIZ (eltrombopag choline): Teva Pharmaceuticals

  • REGN7257: Regeneron Pharmaceuticals

  • PF-06462700: Pfizer

  • Omidubicel: Gamida-Cell

  • Romiplostim: Kyowa Kirin

  • Eltrombopag: Novartis

  • AMG531: Kyowa Kirin

  • Eltrombopag: Novartis

  • Hetrombopag Olamine: Jiangsu HengRui Medicine Co., Ltd.

  • Ibrutinib: Janssen Scientific Affairs, LLC

 

Discover more about therapies set to grab major Aplastic Anemia market share @ Aplastic Anemia Treatment Market

 

Aplastic Anemia Market Drivers

  • Increasing awareness and improved diagnosis: Greater awareness among healthcare professionals and advancements in diagnostic techniques are leading to earlier and more accurate detection of aplastic anemia.

  • Advancements in treatment options: The development of immunosuppressive therapies, hematopoietic stem cell transplantation, and novel targeted therapies is improving patient outcomes and driving market growth.

  • Growing investment in rare disease research: Pharmaceutical companies and research organizations are increasing investments in rare hematologic disorders, supporting new drug development.

  • Rising healthcare expenditure: Improved access to advanced healthcare facilities and treatment options is contributing to increased adoption of therapies.

 

Aplastic Anemia Market Barriers

  • High cost of treatment: Advanced therapies such as stem cell transplantation and long-term immunosuppressive treatments can be expensive, limiting accessibility.

  • Limited donor availability for transplantation: Successful hematopoietic stem cell transplantation often depends on compatible donors, which can restrict treatment options.

  • Adverse effects associated with therapies: Immunosuppressive treatments and transplantation procedures may cause significant side effects and complications.

  • Limited patient population: As a rare disease, the smaller patient pool may restrict market expansion and reduce commercial incentives for drug development.

  • Regulatory and clinical trial challenges: Stringent regulatory requirements and difficulties in recruiting patients for trials can delay the approval of new therapies.

 

Scope of the Aplastic Anemia Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Aplastic Anemia Companies: Teva Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui Medicine Co., Ltd., Janssen Scientific Affairs, LLC, and others

  • Key Aplastic Anemia Therapies: ALVAIZ (eltrombopag choline), PF-06462700, REGN7257, Omidubicel, Romiplostim, Eltrombopag, AMG531, Eltrombopag, Hetrombopag Olamine, Ibrutinib, and others

  • Aplastic Anemia Therapeutic Assessment: Aplastic Anemia current marketed and Aplastic Anemia emerging therapies

  • Aplastic Anemia Market Dynamics: Aplastic Anemia market drivers and Aplastic Anemia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Aplastic Anemia Unmet Needs, KOL’s views, Analyst’s views, Aplastic Anemia Market Access and Reimbursement

 

To know more about Aplastic Anemia companies working in the treatment market, visit @ Aplastic Anemia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Aplastic Anemia Market Report Introduction

2. Executive Summary for Aplastic Anemia

3. SWOT analysis of Aplastic Anemia

4. Aplastic Anemia Patient Share (%) Overview at a Glance

5. Aplastic Anemia Market Overview at a Glance

6. Aplastic Anemia Disease Background and Overview

7. Aplastic Anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Aplastic Anemia

9. Aplastic Anemia Current Treatment and Medical Practices

10. Aplastic Anemia Unmet Needs

11. Aplastic Anemia Emerging Therapies

12. Aplastic Anemia Market Outlook

13. Country-Wise Aplastic Anemia Market Analysis (2022–2036)

14. Aplastic Anemia Market Access and Reimbursement of Therapies

15. Aplastic Anemia Market Drivers

16. Aplastic Anemia Market Barriers

17. Aplastic Anemia Appendix

18. Aplastic Anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aplastic Anemia Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Pfizer, Regeneron Pharma, Gamida-Cell, Kyowa Kirin, Novartis, Jiangsu HengRui

Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics

The Key Acromegaly Companies in the market include – Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others.

 

DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Acromegaly, offering comprehensive insights into the Acromegaly revenue trends, prevalence, and treatment landscape. The report delves into key Acromegaly statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Acromegaly therapies. Additionally, we cover the landscape of Acromegaly clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Acromegaly treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Acromegaly space.

 

Get a Free sample for the Acromegaly Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/acromegaly-market

 

Some of the key facts of the Acromegaly Market Report:

  • The Acromegaly market size was valued ~USD 1,300 million in 2023 and is expected to grow with a significant CAGR during the study period (2022-2036).

  • In January 2026, Camurus announced that the US Food and Drug Administration (FDA) had accepted for review the resubmitted New Drug Application (NDA) for CAM2029 (Oclaiz), an octreotide extended-release injection, for the treatment of patients with acromegaly. The application has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026.

  • In January 2026, Marea announced positive Phase I topline results for MAR002 in acromegaly, highlighting potential for best-in-class efficacy and a favorable dosing profile.

  • In December 2025, Debiopharm announced that the first patient had been randomized in the Phase III (OXTEND-03) clinical trial for adults with acromegaly who are currently maintained on somatostatin analogs.

  • In February 2026, Crinetics Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the marketing authorization of PALSONIFY (paltusotine) for the treatment of adult patients with acromegaly. The opinion has been forwarded to the European Commission (EC), which will make the final approval decision.

  • According to estimates, the total acromegaly market size in 7MM was approximately USD 1,300 million in 2025, with the United States accounting for the largest share, and the market is projected to grow at a significant CAGR through 2036.

  • In 2025, among the EU4 and the UK, the UK held the largest market share, followed by Germany, while Spain accounted for the smallest share.

  • According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of acromegaly in the 7MM was ~59,000.

  • In the United States, acromegaly has an estimated incidence of ~2–11 new cases per million annually, with approximately 20,000–45,000 prevalent cases, though the true burden is likely underestimated due to underdiagnosis.

  • The total diagnosed prevalent cases of acromegaly in the United States were estimated at ~27,500 in 2025, and are projected to increase by 2036, driven by improved detection and greater disease awareness.

  • In the United States, ~95% of cases are attributed to pituitary adenomas, while only ~5% arise from non-pituitary sources, underscoring the dominant role of pituitary-origin disease.

  • Acromegaly demonstrates a slight female predominance (~51% vs. ~49% in males), with most patients diagnosed in their 40s to 50s, reflecting the slow and progressive nature of the disease.

  • In EU4 and the UK countries, Germany had the highest number of diagnosed prevalent cases, while Spain had the least.

  • Based on tumor size, acromegaly is classified into microadenoma and macroadenoma, which are key determinants of disease severity and treatment strategy.

  • Key Acromegaly Companies: Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others.

  • Key Acromegaly Therapies: Paltusotine (PALSONIFY), CAM2029 (OCZYESA), Octreotide (MYCAPSSA), Debio 4126, ALXN2420, MAR002, MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others.

  • The Acromegaly market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acromegaly pipeline products will significantly revolutionize the Acromegaly market dynamics.

  • In 2023, the United States had the highest number of diagnosed prevalent cases of acromegaly in the 7MM, with approximately 27,000 cases, followed by Japan with around 9,000 cases.

  • In the United States, gender-specific cases of acromegaly in 2023 were approximately 13,000 in males and around 14,000 in females.

  • In the US, tumor size-specific cases of acromegaly in 2023 were approximately 75% for macroadenomas and 25% for microadenomas, with numbers expected to rise.

  • In the EU4 and the UK, tumor origin-specific cases of acromegaly in 2023 included approximately 20,300 cases from pituitary tumors and around 1,060 cases from non-pituitary tumors.

 

Acromegaly Overview

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone (GH), typically due to a benign tumor called a pituitary adenoma. This excess GH causes abnormal growth of bones and tissues, leading to enlarged hands, feet, and facial features. Symptoms can develop slowly over years, often resulting in delayed diagnosis. If untreated, acromegaly can lead to serious health complications, including diabetes, hypertension, arthritis, and cardiovascular disease. Treatments include surgery, medication, and radiation therapy to reduce GH levels and manage symptoms.

 

To Know in detail about the Acromegaly market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acromegaly Market Forecast

 

Acromegaly Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acromegaly Epidemiology Segmentation:

The Acromegaly market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of Acromegaly Occurrence

  • Tumor Origin-specific Diagnosed Prevalent Cases of Acromegaly

  • Gender-specific Diagnosed Prevalent Cases of Acromegaly

  • Tumor Size-specific Diagnosed Prevalent Cases of Acromegaly

  • Total Treated Cases of Acromegaly

 

Download the report to understand which factors are driving Acromegaly epidemiology trends @ Acromegaly Epidemiology Forecast

 

Acromegaly Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acromegaly market or expected to get launched during the study period. The analysis covers Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acromegaly Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Acromegaly Therapies and Key Companies

  • Paltusotine (PALSONIFY): Crinetics

  • CAM2029 (OCZYESA): Camurus

  • Octreotide (MYCAPSSA): Chiesi

  • Debio 4126: Debiopharm International SA

  • ALXN2420: AstraZeneca

  • MAR002: Marea Therapeutics

  • MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma

  • SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals

  • Paltusotine (CRN 00808): Crinetics Pharmaceuticals

  • CAM2029 (octreotide subcutaneous depot): Camurus AB

  • GHR-LRX: Ionis Pharmaceuticals

  • Lanreotide A Autogel®: Ipsen

 

Discover more about therapies set to grab major Acromegaly market share @ Acromegaly Treatment Landscape

 

Acromegaly Market Drivers

  • Increasing Awareness and Early Diagnosis: Improved awareness among healthcare professionals and advancements in diagnostic techniques are facilitating earlier detection of acromegaly.

  • Advancements in Targeted Therapies: The development of novel somatostatin analogs, growth hormone receptor antagonists, and other targeted treatments is enhancing disease management.

  • Growing Adoption of Long-Acting Formulations: Long-acting injectable therapies improve patient convenience, adherence, and treatment outcomes, driving market growth.

  • Rising Healthcare Expenditure: Increased investments in endocrinology care and rare disease management are supporting access to advanced therapies.

 

Acromegaly Market Barriers

  • Rare Disease Prevalence: The relatively small patient population limits the overall market size and commercial opportunities.

  • Delayed Diagnosis: Acromegaly symptoms often develop gradually and may be mistaken for other conditions, leading to delayed diagnosis and treatment.

  • High Cost of Treatment: Advanced biologics and long-term therapy requirements can impose a significant financial burden on patients and healthcare systems.

  • Limited Access in Developing Regions: Inadequate healthcare infrastructure and limited availability of specialized endocrinology services may restrict treatment access.

  • Treatment-Related Side Effects: Certain therapies may be associated with gastrointestinal, metabolic, or injection-site adverse effects that can affect patient compliance.

 

Scope of the Acromegaly Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Acromegaly Companies: Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Amryt Pharma/Chiasma, Recordati/Novartis Pharmaceuticals, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Ipsen, and others

  • Key Acromegaly Therapies: Paltusotine (PALSONIFY), CAM2029 (OCZYESA), Octreotide (MYCAPSSA), Debio 4126, ALXN2420, MAR002, MYCAPSSA (octreotide acetate), SIGNIFOR LAR (pasireotide), Paltusotine (CRN 00808), GHR-LRX, CAM2029 (octreotide subcutaneous depot), Lanreotide Autogel®, and others

  • Acromegaly Therapeutic Assessment: Acromegaly current marketed and Acromegaly emerging therapies

  • Acromegaly Market Dynamics: Acromegaly market drivers and Acromegaly market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Acromegaly Unmet Needs, KOL’s views, Analyst’s views, Acromegaly Market Access and Reimbursement

 

To know more about Acromegaly companies working in the treatment market, visit @ Acromegaly Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Acromegaly Market Report Introduction

2. Executive Summary for Acromegaly

3. SWOT analysis of Acromegaly

4. Acromegaly Patient Share (%) Overview at a Glance

5. Acromegaly Market Overview at a Glance

6. Acromegaly Disease Background and Overview

7. Acromegaly Epidemiology and Patient Population

8. Country-Specific Patient Population of Acromegaly

9. Acromegaly Current Treatment and Medical Practices

10. Acromegaly Unmet Needs

11. Acromegaly Emerging Therapies

12. Acromegaly Market Outlook

13. Country-Wise Acromegaly Market Analysis (2022–2036)

14. Acromegaly Market Access and Reimbursement of Therapies

15. Acromegaly Market Drivers

16. Acromegaly Market Barriers

17. Acromegaly Appendix

18. Acromegaly Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics